Feasibility and acceptability of electronic EQ-5D-5L for routine measurement of HRQOL in patients with chronic musculoskeletal problems in Hong Kong primary care

Table 2 Feasibility and acceptability of e-EQ-5D-5L/VAS at baseline and follow-up

Patient perspective	Baseline	1st follow-up	2nd follow-up	p-value
Feasibility	N = 665	N = 595	N = 460	–
Completion rate^a of e-EQ-5D-5L/VAS (% (n))	99.8 (664)	100.0 (595)	100.0 (459)	–
Response rate^b of e-EQ-5D-5L	100%	91.11%	90.00%
Time to complete e-EQ-5D-5L/VAS (in seconds) (mean ± SD)^§	120.66 ± 110.74 (665)	83.99 ± 57.16 (544)#	105.22 ± 82.93 (334)#	< 0.001
Perceived Ease of Use	N = 635	N = 567	N = 401
Overall Agree/Strongly agree to all items (% (n))^†	37.2 (236)	46.9 (266)	47.1(189)	< 0.001
Summative score (mean ± SD, out of 20)^§	12.26 ± 3.82	13.00 ± 3.57	13.22 ± 3.27	< 0.001
Perceived Usefulness	N = 635	N = 567	N = 401
Agree/Strongly agree to at least one item (% (n))^†	85.5 (543)	86.9 (493)	85.3 (342)	0.221
Summative score (mean ± SD, out of 20)^§	14.65 ± 2.37	14.78 ± 2.45	14.49 ± 2.68	0.173

Doctor perspective	Baseline (N = 655)	1st follow-up (N = 560)	2nd follow-up (N = 415)	p-value
Extra time spent on interpreting e-EQ-5D-5L/VAS (in minutes) (mean ± SD)^§	2.02 ± 1.51	1.72 ± 1.28	1.66 ± 2.00	0.006
Perceived ease of use
Overall Agree/Strongly agree to all items (% (n))^†	76.2 (499)	79.3 (444)	85.1 (353)	< 0.001
Summative score (mean ± SD, out of 10)^§	7.74 ± 1.07	7.83 ± 1.20	7.95 ± 1.10	0.007
Perceived usefulness
Agree/Strongly agree to at least one item (% (n)) ^†	72.0 (471)	69.2 (387)	72.0 (299)	0.160
Summative score (mean ± SD, out of 15)^§	10.89 ± 1.93	11.14 ± 2.14	11.22 ± 2.07	0.022

e-EQ-5D-5L/VAS electronic five-level: Euroqol 5 dimension and visual analog scale
^aCompletion rate = the number of e-EQ-5D-5L/VAS that were fully answered divided by the total number of attempted e-EQ-5D-5L/VAS
^bResponse rate = the number of subjects who had repeated the e EQ-5D-5L/VASs divided by the total number of subjects who had attended the follow-up in the clinics
^†Chi-square was used for analysis
^§Repeated measure ANOVA was used for analysis, which only included subjects with both valid Baselines, 1st follow-up and 2nd follow-up data;
^#The data on completion time of e-EQ-5D-5L/VAS during follow-ups were available only for subjects followed up after 23 March, 2021

ISSN: 1477-7525